New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors

  • Lawrence B
  • Gustafsson B
  • Kidd M
 et al. 
  • 14


    Mendeley users who have this article in their library.
  • 10


    Citations of this article.


Successful treatment of unresectable and metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) requires the thoughtful choice of systemic therapy as a component of a multidisciplinary therapeutic approach. The role of somatostatin analogues is established in symptom relief, but the efficacy of interferon and radiopeptide targeted therapy is not clear. The utility of a variety of tyrosine kinase and antiangiogenic agents is variable and under investigation, whereas the role of cytotoxic chemotherapy in poorly differentiated GEP-NETs is accepted. Overall, the ideal treatment of more indolent tumors is less certain. Reassessments of the GEP-NET pathology classification has provided improved logic for the role of a variety of agents, whereas the precise positioning of many new agents that target molecular pathways of angiogenesis and proliferation is under examination. This article describes the current options for systemic therapy for GEP-NETs within the framework of the current World Health Organization classification system. © 2010 Elsevier Inc.

Author-supplied keywords

  • Antineoplastic
  • Biotherapy
  • Carcinoid
  • Chemotherapy
  • Neuroendocrine tumor

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Ben Lawrence

  • Bjorn I. Gustafsson

  • Mark Kidd

  • Irvin Modlin

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free